Melina E. Marmarelis

1.7k total citations
61 papers, 590 citations indexed

About

Melina E. Marmarelis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Melina E. Marmarelis has authored 61 papers receiving a total of 590 indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 15 papers in Cancer Research. Recurrent topics in Melina E. Marmarelis's work include Lung Cancer Treatments and Mutations (44 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Lung Cancer Diagnosis and Treatment (15 papers). Melina E. Marmarelis is often cited by papers focused on Lung Cancer Treatments and Mutations (44 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Lung Cancer Diagnosis and Treatment (15 papers). Melina E. Marmarelis collaborates with scholars based in United States, Japan and France. Melina E. Marmarelis's co-authors include Charu Aggarwal, Corey J. Langer, Roger B. Cohen, Joshua Bauml, F. Stephen Hodi, Christine Ciunci, Xinqi Wu, Aditi P. Singh, Jeffrey C. Thompson and Wei‐Ting Hwang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Melina E. Marmarelis

51 papers receiving 586 citations

Peers

Countries citing papers authored by Melina E. Marmarelis

Since Specialization

Citations

This map shows the geographic impact of Melina E. Marmarelis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melina E. Marmarelis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melina E. Marmarelis more than expected).

Fields of papers citing papers by Melina E. Marmarelis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melina E. Marmarelis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melina E. Marmarelis. The network helps show where Melina E. Marmarelis may publish in the future.

Co-authorship network of co-authors of Melina E. Marmarelis

This figure shows the co-authorship network connecting the top 25 collaborators of Melina E. Marmarelis. A scholar is included among the top collaborators of Melina E. Marmarelis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melina E. Marmarelis. Melina E. Marmarelis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. 2024 ·Journal of Clinical Oncology ·Natasha B. Leighl, Hiroaki Akamatsu, (unknown), Ying Cheng, Anna Minchom, Melina E. Marmarelis, Rachel E. Sanborn, James Chih‐Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massutí, Alexander I. Spira, (unknown), (unknown), Ali Alhadab, Remy B. Verheijen, Mohamed Gamil, Joshua Bauml, Mahadi Baig, Antonio Passaro	12
2	Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy 2024 ·Clinical Lung Cancer ·(unknown), Adam Barsouk, (unknown), Margaret Stalker, Jonathan Sussman, Kyle Robinson, John A. Kosteva, Aditi Singh, Roger B. Cohen, Corey J. Langer, (unknown), Christopher D’Avella, Lova Sun, Melina E. Marmarelis, Charu Aggarwal	2
3	Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) treated with osimertinib (osi) vs. Afatinib or erlotinib 2024 ·Lung Cancer ·Adam Barsouk, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), K M Goel, (unknown), (unknown), (unknown), Benjamin Aaron Bleiberg, Lova Sun, Aditi P. Singh, Roger B. Cohen, Charų C. Aggarwal, Melina E. Marmarelis, Corey J. Langer	1
4	Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2. 2024 ·Journal of Clinical Oncology ·Byoung Chul Cho, Yongsheng Wang, Enriqueta Felip, Jiuwei Cui, Alexander I. Spira, Joel W. Neal, Christina S. Baik, Melina E. Marmarelis, Eiki Ichihara, Jong Seok Lee, Se‐Hoon Lee, James Chih‐Hsin Yang, Sebastian Michels, Zacharias Anastasiou, Joshua C. Curtin, (unknown), Isabelle Leconte, Leonardo Trani, Mahadi Baig, Pascale Tomasini	12
5	P2.31-05 Determining Lines of Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Using Real-World Data 2023 ·Journal of Thoracic Oncology ·(unknown), Lova Sun, Joshua E. Reuss, (unknown), Geoffrey Liu, (unknown), Stephen V. Liu, (unknown), Tejas Patil, Jorge J. Nieva, (unknown), Kristen A. Marrone, Vincent K. Lam, William Schwartzman, (unknown), Keith L. Miller, D. Ross Camidge, Charu Aggarwal, Wei‐Ting Hwang, Melina E. Marmarelis	0
6	Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer 2023 ·JCO Precision Oncology ·Charu Aggarwal, Melina E. Marmarelis, Wei‐Ting Hwang, (unknown), (unknown), Aditi P. Singh, Lova Sun, John A. Kosteva, (unknown), Roger B. Cohen, Corey J. Langer, Abigail Doucette, Peter Gabriel, Lawrence N. Shulman, Katharine A. Rendle, Jeffrey C. Thompson, Justin E. Bekelman, Erica L. Carpenter	22
7	A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer 2023 ·The Oncologist ·Charu Aggarwal, (unknown), Joshua Bauml, (unknown), Tomás S. Alemán, Christine Ciunci, Christopher D’Avella, (unknown), (unknown), (unknown), Lova Sun, Aditi P. Singh, Melina E. Marmarelis, Roger E. Cohen, Corey J. Langer, Ravi K. Amaravadi	13
8	A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer 2023 ·Clinical Lung Cancer ·Wade T. Iams, (unknown), Sharon Phillips, Adrian G. Sacher, Christine M. Bestvina, Vamsidhar Velcheti, Xiao Wang, Melina E. Marmarelis, Nan Sethakorn, Ticiana Leal, Paul Sackstein, Chul Kim, (unknown), Kathan Mehta, (unknown), Jorge J. Nieva, Tejas Patil, D. Ross Camidge	2
9	Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression 2023 ·Clinical Lung Cancer ·(unknown), Nikhil Yegya‐Raman, Siqi Zhang, (unknown), Roger B. Cohen, Charu Aggarwal, Jeffrey C. Thompson, Melina E. Marmarelis, William P. Levin, Keith A. Cengel, Christine Ciunci, Aditi P. Singh, Christopher D’Avella, Christiana Davis, Corey J. Langer, Steven J. Feigenberg	7
10	Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors 2023 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), Sang Ho Lee, Bolin Li, (unknown), William P. Levin, Keith A. Cengel, Lova Sun, Charu Aggarwal, Melina E. Marmarelis, Abigail Doucette, Roger B. Cohen, Ying Xiao, Corey J. Langer, Jeffrey D. Bradley, Steven J. Feigenberg, Nikhil Yegya‐Raman	9
11	Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma 2023 ·JAMA Network Open ·Melina E. Marmarelis, Xiao Wang, Leonid Roshkovan, (unknown), John T. Miura, Michelle S. Ginsberg, (unknown), Jacklynn V. Egger, (unknown), Andrea Cercek, Michael B. Foote, Leslie A. Litzky, Garrett M. Nash, Andrew R. Haas, Giorgos C. Karakousis, Keith A. Cengel, Sharyn I. Katz, Marjorie G. Zauderer, Corey J. Langer, Michael Offin	7
12	Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC). 2023 ·Journal of Clinical Oncology ·Melina E. Marmarelis, (unknown), Caroline E. McCoach, (unknown), Geoffrey Liu, Devalben Patel, Jorge J. Nieva, Kristen A. Marrone, Vamsidhar Velcheti, Stephen V. Liu, Tejas Patil, Jared Weiss, William Schwartzman, Liza C. Villaruz, (unknown), Dara L. Aisner, Wei‐Ting Hwang, Charu Aggarwal, D. Ross Camidge, Lova Sun	0
13	Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens 2023 ·Clinical Lung Cancer ·(unknown), Wei‐Ting Hwang, Yu‐Xiao Yang, Aditi P. Singh, Christine Ciunci, Christopher D’Avella, Charu Aggarwal, Roger B. Cohen, Corey J. Langer, Ronac Mamtani, Melina E. Marmarelis	1
14	Systemic Therapy for Mutation-Driven NSCLC 2021 ·Seminars in Radiation Oncology ·Lova Sun, Melina E. Marmarelis, Corey J. Langer	5
15	Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma 2021 ·Lung Cancer ·Roger Y. Kim, Yimei Li, Melina E. Marmarelis, Anil Vachani	6
16	Outcomes in Patients With Non–small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy 2020 ·Clinical Lung Cancer ·Lova Sun, Christiana Davis, Wei‐Ting Hwang, (unknown), (unknown), Melina E. Marmarelis, Aditi P. Singh, Abigail T. Berman, Steven J. Feigenberg, William P. Levin, Christine Ciunci, Joshua Bauml, Roger B. Cohen, Corey J. Langer, Charu Aggarwal	30
17	Treatment of Patients With Non–Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations 2020 ·Clinical Lung Cancer ·Melina E. Marmarelis, Corey J. Langer	3
18	MA05.10 Pembrolizumab in the Treatment of Patients with Malignant Pleural Mesothelioma Following Progression After Initial Chemotherapy 2019 ·Journal of Thoracic Oncology ·Keith A. Cengel, Sharyn I. Katz, Leonid Roshkovan, (unknown), (unknown), (unknown), Melissa Culligan, (unknown), Sunil Singhal, (unknown), Christine Ciunci, Melina E. Marmarelis, Evan Alley, Corey J. Langer	0
19	P1.01-64 Impact of STK11 Co-Mutation on Outcomes Following Immunotherapy Among Patients with TP53 and KRAS Mutated Stage IV NSCLC 2018 ·Journal of Thoracic Oncology ·Melina E. Marmarelis, Erin M. Bange, Stephen Bagley, Wei‐Ting Hwang, Yun Yang, Jeffrey C. Thompson, Joshua Bauml, Christine Ciunci, Evan Alley, Jennifer D. Morrissette, Roger B. Cohen, Corey J. Langer, Erica L. Carpenter, Charu Aggarwal	2
20	Diabetes mellitus and community-acquired bloodstream infections in the critically ill 2013 ·Journal of Critical Care ·(unknown), Melina E. Marmarelis, Mallika L. Mendu, Takuhiro Moromizato, Fiona K. Gibbons, Kenneth B. Christopher	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact